Pharmafile Logo
Pharmafocus logo
Advanced Search

Actelion

Showing 15 posts of 33 posts found.

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

March 4, 2021
Actelion, Batten disease, Janssen

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News
actelion

Actelion spin-off hit by blow shortly before buyout

June 9, 2017
Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ

Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …

News
janeg

J&J lines up its Global Head for Actelion

May 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson

The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …

Appointment
janssen_latest_logo_on_sign

Janssen acquires over 90% of Actelion

April 24, 2017
Sales and Marketing Actelion, Janssen

Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of …

News
actelion

EMA green lights Actelion’s drug after patient deaths scare

April 10, 2017
Sales and Marketing Actelion, Johnson & Johnson, Uptravi

The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …

News
pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News
jj

J&J finally seals $30 billion deal for Actelion

January 26, 2017
Sales and Marketing Actelion, Janssen, Johnson & Johnson

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …

News
jj_2johnson_and_johnson

Actelion acquisition hokey-cokey continues with J&J returning to table

December 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

The Actelion takeover saga continues with Johnson & Johnson back in the game, and now re-entering into exclusive negotiations. Actelion …

News
actelion

Sanofi eyes Actelion merger as J&J backs down

December 14, 2016
Medical Communications, Research and Development, Sales and Marketing Actelion, Johnson & Johnson, Sanofi

After days of negotiations, Johnson and Johnson has stepped down from its attempts to acquire Swiss blood-pressure specialist Actelion, while …

News

J&J reportedly poised to acquire Europe’s biggest biotech

November 25, 2016
Sales and Marketing Actelion, J&J, JJ, Johnson and Johnson, acquisition

Johnson & Johnson could be eyeing a takeover of Swiss biotech Actelion, Europe’s biggest biotech, according to insiders, Bloomberg has …

News
actelion_logo

Actelion says blood pressure drug Uptravi now available in Germany

June 15, 2016
Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch

Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany.  The European Commission granted …

News
actelion

Actelion granted EU approval for hypertension treatment

May 17, 2016
Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension

Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …

News
actelion_logo

Actelion ups outlook for 2016, reports Q1 net income up 12%

April 22, 2016
Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook

Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …

News
Actelion logo

Actelion’s Uptravi goes on sale

January 5, 2016
Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag

Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …

News

Latest content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023

FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System

November 29, 2023

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023